Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013. [More]
Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter is associated with an increased risk for heart attack. Moreover, this association can already be observed in levels of particulate exposure below the current specified European limit values. [More]

Study finds that Mediterranean diet may also prevent peripheral artery disease

A multicenter study that previously reported a reduction in heart attack and stroke with a Mediterranean diet supplemented with extra-virgin olive oil or with nuts now also reports a lower risk of peripheral artery disease, according to a study in the January 22/29 issue of JAMA. [More]

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection. [More]
Vitamin D deficiency may lead to stiffening of blood vessels

Vitamin D deficiency may lead to stiffening of blood vessels

UV-B radiation in sunlight is the most important factor for the production of vitamin D, and that is why many people suffer from low levels of vitamin D during the winter months. [More]
Higher vitamin D levels linked with better cognition and less depression in PD patients

Higher vitamin D levels linked with better cognition and less depression in PD patients

A new study exploring vitamin D levels in patients with Parkinson's disease (PD) opens up the possibility of a new avenue of early intervention that may delay or prevent the onset of cognitive impairment and depression. The findings are published in the Journal of Parkinson's Disease. [More]
FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Low doses of anticancer drug can prevent development of diabetes mellitus type 1

Low doses of anticancer drug can prevent development of diabetes mellitus type 1

Very low doses of a drug used to treat certain types of cancer protect the insulin-producing cells in the pancreas and prevent the development of diabetes mellitus type 1 in mice. The medicine works by lowering the level of so-called sterile inflammation. The findings have been made by researchers from the University of Copenhagen, the Technical University of Denmark and the University of Southern Denmark working with researchers in Belgium, Italy, Canada, Netherlands and the USA. [More]
Study links dietary fat content with excess of abdominal fat in adolescents, irrespective of physical exercise

Study links dietary fat content with excess of abdominal fat in adolescents, irrespective of physical exercise

The prevalence of excess weight and obesity among adolescents and, as a result, the concomitant problems, has increased considerably in recent years. A study by the UPV/EHU has confirmed that, irrespective of the total calories consumed and the physical activity done, an excessive proportion of fat in the diet leads to a greater accumulation of fat in the abdomen. [More]
FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy. [More]
RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

RegeneRx's Tβ4 gets FDA Orphan Drug designation for treatment of Neurotrophic Keratopathy

RegeneRx Biopharmaceuticals, Inc. announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development for its drug candidate, Thymosin beta 4 (Tβ4), for the treatment of Neurotrophic Keratopathy, a serious degenerative disease of the corneal epithelium (the outside layer of the eye). [More]
Researchers uncover new genetic clue that contributes to increased risk of type 2 diabetes

Researchers uncover new genetic clue that contributes to increased risk of type 2 diabetes

​An international team of researchers in Mexico and the United States has uncovered a new genetic clue that contributes to an increased risk of developing type 2 diabetes, particularly the elevated risk among Mexican and other Latin American populations. [More]

Most frequent reasons for readmission often related to patients' underlying chronic medical conditions

Researchers cite identification and monitoring of known underlying chronic medical conditions as opportunities to reduce readmission rates and improve patient safety. [More]
New treatment options for diabetic wound healing in cornea and skin

New treatment options for diabetic wound healing in cornea and skin

Diabetes Mellitus (DM), a metabolic disorder that affects nearly 170 million people worldwide, is characterized by chronic hyperglycemia that disrupts carbohydrate fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. DM can cause long-term damage, dysfunction and even failure of various organs. [More]

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD). [More]
New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

The prevalence of chronic fatigue syndrome in children and the significant impairment it causes to their physical functioning, school attendance and performance, and extracurricular activities, are at the root of a new Chicago-based study led by DePaul University psychologist Leonard A. Jason. [More]

Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

Cardiovascular complications and hypoglycemia (low blood sugar) were common nonfatal complications in adults 60 years of age and older with diabetes, according to a study published by JAMA Internal Medicine, a JAMA Network publication. [More]
Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. [More]

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. [More]